<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>37. Anogenital Warts– First episode warts (includes failures)</title>
		<description>Discuss 37. Anogenital Warts– First episode warts (includes failures)</description>
		<link>https://www.pathwayanalytics.com/16-sexual-health-pathways/sti-intervention-b/37-anogenital-warts-first-episode-warts-includes-failures</link>
		<lastBuildDate>Thu, 23 Apr 2026 16:29:09 +0100</lastBuildDate>
		<generator>JComments</generator>
		<atom:link href="https://www.pathwayanalytics.com/component/jcomments/feed/com_content/37" rel="self" type="application/rss+xml" />
		<item>
			<title>Pathway Analytics says:</title>
			<link>https://www.pathwayanalytics.com/16-sexual-health-pathways/sti-intervention-b/37-anogenital-warts-first-episode-warts-includes-failures#comment-210</link>
			<description><![CDATA[[CM]Proposed: Error Steps 8 & 9 should be a factor of 3 x 30% = 90% not 300% Dose for Aldara is 12- sachet pack per month, treament covers 4 months. Steps 5 and 7 should reflect 40% x 12 sachet pack x 4 x patients remaining. Aldara patients also require a single follow-up consultation by Blend Dr N6/7 for 15mins consultation etc. Patients receiving Warticon Agreed summary reflects BASHH guidelines First Episode: Of 100% patients: 30% Cryo - 4 treatments over 4 visits 30% Warticon - 1 month supply administered at home (no further visits) 40% Aldera - 4 months supply administered at home and 1 check-up visit Of 100% of patients: 60% - success - no further action 40% - fail and continue treatment as follows: 30% Cryo - 4 treatments over 4 visits 10% Warticon - 1 month supply administered at home (no further visits) 60% Aldera - 4 months supply administered at home and 1 check-up visit Review currency allocation]]></description>
			<dc:creator>Pathway Analytics</dc:creator>
			<pubDate>Wed, 15 Feb 2017 15:47:02 +0000</pubDate>
			<guid>https://www.pathwayanalytics.com/16-sexual-health-pathways/sti-intervention-b/37-anogenital-warts-first-episode-warts-includes-failures#comment-210</guid>
		</item>
		<item>
			<title>Pathway Analytics says:</title>
			<link>https://www.pathwayanalytics.com/16-sexual-health-pathways/sti-intervention-b/37-anogenital-warts-first-episode-warts-includes-failures#comment-153</link>
			<description><![CDATA[[CM]Proposed/CA G Agreed/Changed Step 4: Increase surrounding visit activity around Warts- Cryotherapy course treatment for 5 five further visits (register M&G, 15 min Examination treatment and spray Band 5) Change weightings Cryotherapy to 30% Aldara 40% Warticon 30% Step 9: Increase surrounding visit activity around Warts- Cryotherapy course treatment for 5 five further visits (register M&G, 15 min Examination treatment and spray Band 5) Increase surrounding visit activity around Warticon and Aldara course treatment for 30% for one further visits (register M&G, 15 min Examination treatment and spray Dr Nurse 6/7) Change intervention weightings to: Cryotherapy to 30% Aldara 60% Warticon 10%]]></description>
			<dc:creator>Pathway Analytics</dc:creator>
			<pubDate>Wed, 08 Jun 2016 13:43:54 +0100</pubDate>
			<guid>https://www.pathwayanalytics.com/16-sexual-health-pathways/sti-intervention-b/37-anogenital-warts-first-episode-warts-includes-failures#comment-153</guid>
		</item>
		<item>
			<title>Michael Brady says:</title>
			<link>https://www.pathwayanalytics.com/16-sexual-health-pathways/sti-intervention-b/37-anogenital-warts-first-episode-warts-includes-failures#comment-151</link>
			<description><![CDATA[The cryotherapy visits (6 in initial diagnosis) and 6 for those who have recurrences need to be costed - they will each have a visit with associated cost]]></description>
			<dc:creator>Michael Brady</dc:creator>
			<pubDate>Wed, 08 Jun 2016 13:07:26 +0100</pubDate>
			<guid>https://www.pathwayanalytics.com/16-sexual-health-pathways/sti-intervention-b/37-anogenital-warts-first-episode-warts-includes-failures#comment-151</guid>
		</item>
	</channel>
</rss>
